Network modeling suggests HIV infection phenocopies PI3K-AKT pathway mutations to enhance HPV-associated cervical cancer.
Journal
Molecular omics
ISSN: 2515-4184
Titre abrégé: Mol Omics
Pays: England
ID NLM: 101713384
Informations de publication
Date de publication:
14 08 2023
14 08 2023
Historique:
pmc-release:
14
08
2024
medline:
15
8
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
epublish
Résumé
Women coinfected with human immunodeficiency virus type 1 (HIV-1) and human papillomavirus (HPV) are six times as likely to develop invasive cervical carcinoma compared to those without HIV. Unlike other HIV-associated cancers, the risk of cervical cancer development does not change when HPV/HIV coinfected women begin antiretroviral therapy, suggesting HIV-associated immune suppression is not a key driver of cervical cancer development in coinfected women. Here, we investigated whether the persistent secretion of inflammatory factors in HIV-positive patients on antiretroviral therapy could enhance cancer signaling in HPV-infected cervical cells
Identifiants
pubmed: 37204043
doi: 10.1039/d3mo00025g
pmc: PMC10524288
mid: NIHMS1903501
doi:
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
538-551Subventions
Organisme : NIAID NIH HHS
ID : K99 AI163868
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA239333
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA274502
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA209891
Pays : United States
Organisme : NIAID NIH HHS
ID : P50 AI150476
Pays : United States
Organisme : NIAID NIH HHS
ID : U54 AI170792
Pays : United States
Références
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Clin Cancer Res. 2015 Dec 1;21(23):5360-70
pubmed: 26080840
Bioinformatics. 2010 Dec 15;26(24):3135-7
pubmed: 21123224
CA Cancer J Clin. 2021 Nov;71(6):505-526
pubmed: 34499351
BMC Cancer. 2021 Apr 20;21(1):432
pubmed: 33879103
Medicine (Baltimore). 2018 Aug;97(31):e11392
pubmed: 30075505
PLoS Comput Biol. 2017 Oct 12;13(10):e1005598
pubmed: 29023449
Nat Genet. 1994 Aug;7(4):480-4
pubmed: 7951317
J Natl Cancer Inst. 1964 Jan;32:135-63
pubmed: 14114965
Lancet HIV. 2018 Jan;5(1):e45-e58
pubmed: 29107561
Lancet Glob Health. 2021 Feb;9(2):e161-e169
pubmed: 33212031
Cancer Epidemiol. 2018 Apr;53:81-92
pubmed: 29414636
Br J Cancer. 2013 Jan 15;108(1):234-9
pubmed: 23169283
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6584-9
pubmed: 18451027
Nature. 2011 Dec 21;481(7381):365-70
pubmed: 22190034
Signal Transduct Target Ther. 2021 Feb 24;6(1):78
pubmed: 33623018
Cell. 2021 Jan 7;184(1):106-119.e14
pubmed: 33333024
Front Oncol. 2019 Jan 22;8:682
pubmed: 30723697
Clin Infect Dis. 2019 Oct 15;69(9):1555-1565
pubmed: 30602038
J Clin Oncol. 2016 Nov 1;34(31):3749-3757
pubmed: 27573661
BMC Cancer. 2017 Nov 7;17(1):726
pubmed: 29115946
Mol Med Rep. 2019 Jun;19(6):4529-4535
pubmed: 30942405
J Proteomics. 2022 Feb 10;252:104453
pubmed: 34915198
J Infect Dis. 2013 Dec 1;208(11):1756-67
pubmed: 23908485
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):405-13
pubmed: 23254153
J Med Genet. 2019 Mar;56(3):186-194
pubmed: 30567904
Oncol Lett. 2017 Dec;14(6):7629-7635
pubmed: 29344211
Clin Infect Dis. 2020 Dec 17;71(10):e540-e548
pubmed: 32162657
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Gynecol Cancer. 2012 Nov;22(9):1570-6
pubmed: 23051954
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
pubmed: 17565153
Mol Ther Oncolytics. 2022 Mar 15;25:1-15
pubmed: 35399607
Am J Cancer Res. 2021 May 15;11(5):2005-2024
pubmed: 34094666
Cancer Manag Res. 2019 Jul 30;11:7197-7210
pubmed: 31534369
Open Forum Infect Dis. 2015 Jan 13;2(1):ofu117
pubmed: 25884005
Genomics. 2021 Nov;113(6):3487-3500
pubmed: 34425224
Front Immunol. 2020 Jun 25;11:1349
pubmed: 32670296
Oncotarget. 2016 Aug 30;7(35):57050-57065
pubmed: 27489353
BMC Immunol. 2021 Jan 6;22(1):3
pubmed: 33407095
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
J Transl Med. 2019 Nov 19;17(1):379
pubmed: 31744495
Curr Opin HIV AIDS. 2017 Jan;12(1):6-11
pubmed: 27749369
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Oncol Lett. 2016 Oct;12(4):2389-2394
pubmed: 27698804
Int J Clin Exp Pathol. 2014 Aug 15;7(9):6165-71
pubmed: 25337265
Small GTPases. 2016 Oct;7(4):207-221
pubmed: 27628050
Science. 2021 Oct;374(6563):eabf3066
pubmed: 34591612
Nat Genet. 2020 Aug;52(8):800-810
pubmed: 32747824
BMJ Open. 2017 Aug 4;7(8):e015123
pubmed: 28780541
Int J Gynecol Cancer. 2019 Feb;29(2):242-249
pubmed: 30630884
Clin Infect Dis. 2017 Jan 15;64(2):124-131
pubmed: 27737952
AIDS. 2021 Sep 1;35(11):1851-1856
pubmed: 34049357
Nature. 2014 Feb 20;506(7488):371-5
pubmed: 24390348
J Infect Dis. 2019 Nov 6;220(12):1885-1891
pubmed: 30668739
Bioinformatics. 2008 Mar 1;24(5):719-20
pubmed: 18024473
Acta Cytol. 2019;63(2):148-158
pubmed: 30783048
Virology. 2018 Mar;516:176-188
pubmed: 29407375
Cancer Discov. 2018 Nov;8(11):1474-1489
pubmed: 30209081
PLoS One. 2012;7(2):e30881
pubmed: 22363505
Nat Rev Genet. 2017 Sep;18(9):551-562
pubmed: 28607512
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
AIDS. 2011 Feb 20;25(4):463-71
pubmed: 21139489
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Front Cell Dev Biol. 2020 Jun 12;8:474
pubmed: 32596243
Cancer Biol Ther. 2006 Jun;5(6):684-90
pubmed: 16855377
Int J STD AIDS. 2014 Mar;25(3):163-77
pubmed: 24216030
J Pathol. 2009 Nov;219(3):383-91
pubmed: 19718710
Gynecol Oncol Rep. 2017 Oct 16;22:82-88
pubmed: 29159260
J Clin Invest. 2010 Sep;120(9):3296-309
pubmed: 20679727
Rev Med Virol. 2015 Mar;25 Suppl 1:24-53
pubmed: 25752815
J Cancer. 2019 May 20;10(10):2145-2152
pubmed: 31258717
Front Immunol. 2019 Aug 27;10:1965
pubmed: 31507593
Int J Gynecol Cancer. 2023 Apr 3;33(4):592-597
pubmed: 36368710
Front Cell Infect Microbiol. 2022 Feb 04;12:827717
pubmed: 35186800